Skip to main content

Mirum Pharmaceuticals Inc

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

MIRM$94.42+1.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)

Common Stock · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensive Income (Loss) · TotalStockholders’Equity
Shares · Amount
Balance as of December 31, 202346,723,143$5$803,260$(556,239)$1,644$248,670
Issuance of common stock in connection with equity award plans337,963—1,205——1,205
Stock-based compensation——11,664——11,664
Net loss———(25,279)—(25,279)
Other comprehensive loss————(1,657)(1,657)
Balance as of March 31, 202447,061,1065816,129(581,518)(13)234,603
Issuance of common stock in connection with equity award plans442,652—5,858——5,858
Issuance of common stock in connection with employee stock purchase plan68,089—1,433——1,433
Stock-based compensation——12,196——12,196
Net loss———(24,638)—(24,638)
Other comprehensive loss————(464)(464)
Balance as of June 30, 202447,571,8475835,616(606,156)(477)228,988
Issuance of common stock in connection with equity award plans396,274—3,863——3,863
Stock-based compensation——12,011——12,011
Net loss———(14,235)—(14,235)
Other comprehensive income————1,3971,397
Balance as of September 30, 202447,968,121$5$851,490$(620,391)$920$232,024
Common Stock · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome (Loss) · TotalStockholders’Equity
Shares · Amount
Balance as of December 31, 202236,956,345$4$535,074$(392,824)$(217)$142,037
Issuance of common stock in connection with equity award plans197,703—1,390——1,390
Issuance of common stock in at-the-market offerings, net of issuance costs of $518658,206—14,480——14,480
Issuance of common stock in connection with achievement of Contingent Milestone199,993—4,292——4,292
Stock-based compensation——8,728——8,728
Net loss———(30,130)—(30,130)
Other comprehensive income————353353
Balance as of March 31, 202338,012,2474563,964(422,954)136141,150
Issuance of common stock in connection with equity award plans101,699—803——803
Issuance of common stock in connection with employee stock purchase plan76,481—1,294——1,294
Issuance of common stock in connection with settlement of Indemnification Holdback liability31,631—896——896
Stock-based compensation——8,565——8,565
Net loss———(74,038)—(74,038)
Other comprehensive loss————(60)(60)
Balance as of June 30, 202338,222,0584575,522(496,992)7678,610
Issuance of common stock in private placement, net of issuance costs of $7,7618,000,0001202,238——202,239
Issuance of common stock in connection with equity award plans373,687—4,766——4,766
Stock-based compensation——8,588——8,588
Net loss———(23,588)—(23,588)
Other comprehensive loss————(1,534)(1,534)
Balance as of September 30, 202346,595,745$5$791,114$(520,580)$(1,458)$269,081
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.